amcrasto.doc
99 views | +0 today
Follow
Your new post is loading...
Your new post is loading...
Rescooped by Mohamed Fathi SAFFAR from New drug approvals
Scoop.it!

Role of plants in anticancer drug discovery | EUREKAMOMENTS IN ORGANIC CHEMISTRY

Role of plants in anticancer drug discovery | EUREKAMOMENTS IN ORGANIC CHEMISTRY | amcrasto.doc | Scoop.it

Via Anthony M Crasto DR.
more...
No comment yet.
Rescooped by Mohamed Fathi SAFFAR from New drug approvals
Scoop.it!

Palbociclib

Palbociclib | amcrasto.doc | Scoop.it
  PALBOCICLIB Mechanism of action: selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6 Indication: Estrogen receptor-positive (ER+), HER2-negative (HER2 -) breast cancer Current ...

Via Anthony M Crasto DR.
more...
No comment yet.
Rescooped by Mohamed Fathi SAFFAR from Plant Immunity And Microbial Effectors
Scoop.it!

LysM Effectors: Secreted Proteins Supporting Fungal Life

LysM Effectors: Secreted Proteins Supporting Fungal Life | amcrasto.doc | Scoop.it
by Anja Kombrink, Bart P. H. J. Thomma

Via IPM Lab
Mohamed Fathi SAFFAR's insight:
LysM Effectors: Secreted Proteins Supporting Fungal Life
more...
No comment yet.
Scooped by Mohamed Fathi SAFFAR
Scoop.it!

Antiviral patents released by Roche » All About Drugs

Antiviral patents released by Roche » All About Drugs | amcrasto.doc | Scoop.it
ALL ABOUT DRUGS BY DR ANTHONY MELVIN CRASTO, WORLD DRUG TRACKER, HELPING MILLIONS, MILLION HITS ON GOOGLE, ONE LAKH CONNECTIONS WORLDWIDE.............
more...
No comment yet.
Rescooped by Mohamed Fathi SAFFAR from New drug approvals
Scoop.it!

Microbiology test of water ( IP,BP,USP)

Microbiology test of water ( IP,BP,USP) | amcrasto.doc | Scoop.it
Microbiology test of water ( IP,BP,USP)
OBJECTIVE
Microbiological Test of Water is provided to determine compliance with the requirements given in individual monograph/specifications.

Via Anthony M Crasto DR.
more...
Rescooped by Mohamed Fathi SAFFAR from Pharmaguy's Insights Into Drug Industry News
Scoop.it!

Leaders of U.S. Biotech Call Trump’s Ban “Misguided.” Big #Pharma Still Stands Mutely Behind Trump!

Leaders of U.S. Biotech Call Trump’s Ban “Misguided.” Big #Pharma Still Stands Mutely Behind Trump! | amcrasto.doc | Scoop.it

We the undersigned, founders and leaders of biotech companies, write to express our deep concern and opposition to the executive order signed by President Donald Trump on January 27, 2017, barring the entry of citizens from seven countries into the United States1.

 

The United States is the world’s greatest developer of medicines and new inventions to ameliorate and cure intractable diseases, a status achieved through massive investment in private and public companies, academia and R&D. Most importantly, our success has been founded on the creativity and dedication of our most precious resource—our people.

 

Our people include researchers, clinicians, entrepreneurs and business executives from all over the world. They are colleagues in our laboratories, management teams and boardrooms. They discover and develop therapies that drive US biomedical innovation and deliver new medicines to patients, not only in America, but also across the globe. And they start companies that drive the economic growth and employment provided by biotech. Many of our colleagues from abroad ultimately become Americans, all to the great benefit of the United States. Indeed, a study found that in 2014, 52% of the 69,000 biomedical researchers in the United States were foreign-born.

 

If this misguided policy is not reversed, America is at risk of losing its leadership position in one of its most important sectors, one that will shape the world in the twenty-first century. Indeed, it will harm an industry dominated by smaller companies and startups, the very kind of industry the administration has said it wants to support. It will slow the fight against the many diseases that afflict us, as well as carry negative economic consequences for the United States.

 

From STATnews: “Entirely missing are representatives of Big Pharma, which has been comparatively silent on the issue (“Pharma's Top Execs React to Trump Immigration Ban With Near Universal Silence”; http://sco.lt/8fzALh). Among the world’s largest drug makers, only one, Allergan, has criticized the executive order. The likes of Johnson & Johnson, Pfizer, Merck, and Novartis have either stayed silent or issued statements that expressed support for affected employees but took no stance on the order itself.”

 

Further Reading: “Big Pharma (@PhRMA) Stands Behind Trump Even As He Vows to Lower Prices to Medicare”; http://sco.lt/5461NB


Via Pharma Guy
more...
No comment yet.
Rescooped by Mohamed Fathi SAFFAR from New drug approvals
Scoop.it!

Palbociclib

Palbociclib | amcrasto.doc | Scoop.it
  PALBOCICLIB Mechanism of action: selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6 Indication: Estrogen receptor-positive (ER+), HER2-negative (HER2 -) breast cancer Current ...

Via Anthony M Crasto DR.
more...
No comment yet.
Rescooped by Mohamed Fathi SAFFAR from ORGANIC CHEMISTRY INTERNATIONAL
Scoop.it!

EMEDASTINE DIFUMARATE, EMADINE, 8 TH DEC 2013 PATENT EXPIRY

EMEDASTINE DIFUMARATE, EMADINE,  8 TH DEC 2013 PATENT EXPIRY | amcrasto.doc | Scoop.it
EMEDASTINE DIFUMARATE Emedastine difumarate (Emadine) is a second generation antihistamine used in eye drops to treat allergic conjunctivitis. Its mechanism of action is a H1 receptor antagonist. E...

Via Anthony M Crasto DR.
more...
No comment yet.
Rescooped by Mohamed Fathi SAFFAR from Cardiovascular Disease: PHARMACO-THERAPY
Scoop.it!

Cilostazol Ameliorates Warfarin-Induced Hemorrhagic ... - Stroke

Cilostazol Ameliorates Warfarin-Induced Hemorrhagic ... - Stroke | amcrasto.doc | Scoop.it
Conclusions—Cilostazol reduced the warfarin-related risk of HT after ischemia by protecting the vascular endothelial cells. This result suggested that cilostazol administration in patients with acute ischemic stroke might reduce ...

Via Aviva Lev-Ari, PhD, RN
more...
No comment yet.